Paion Inc., a Mahwah, N.J.-based subsidiary of Aachen, Germany-based Paion AG, has started the second pivotal U.S. phase III trial of remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy.